Scoop.it

NVIDIA recently announced a major expansion of its Clara healthcare platform with new software and tools to help healthcare researchers, technology solutions providers and hospitals tackle the COVID-19 pandemic faster.

The first of this expansion is the availability of NVIDIA Clara Parabricks computational genomics software via a free, 90-day license to COVID-19 researchers. The software is capable of analyzing the whole human genome DNA sequence in under 20 minutes.

NVIDIA also introduced GPU-accelerated RNA-sequencing pipelines that return results in less than 2 hours, giving researchers critical insights into patient susceptibility to disease, its progression and response to treatment.

In addition, NVIDIA released a set of AI models that can help researchers detect and study infected patients through chest CT scan data. Jointly developed by NVIDIA’s applied research team and clinicians and data scientists at the National Institutes of Health (NIH) through a cooperative research and development agreement, the models used data from locations with high rates of COVID-19 infections, including China, Italy, Japan and the United States.

Source: www.healthcareitnews.com

Last week saw Teladoc Health release its 1Q20 financial results giving the US telehealth industry a first glimpse of how COVID-19 is impacting the ambulatory virtual care market. Discussion around the crisis and its impact on telehealth has been rife since early March and the data published by Teladoc Health highlights that this was justified.

The company reported that the number of virtual care consults in the quarter had passed the 2 million mark, up approximately 60% from the 1.24M reported for 4Q19 and up nearly 90% on the 1.06M for the same period in 2019. Much of this growth had been seen over the period from the start to the end of March, with average daily consultations doubling over the month. Teladoc’s forward-looking statements suggest it expects rapid growth to continue into the next quarter as the full impact of COVID runs for three months, with volumes then flattening in the second half of the year, maintaining the new highs but with growth rates falling back to those seen historically.

Source: hitconsultant.net

POCUS technology from Butterfly Network expands screening capabilities, offering "an immediate and clear picture of what’s happening in a patient’s lungs."

Source: www.healthcareitnews.com

Eko's ECG low ejection fraction tool will now be able to help clinicians spot cardiac complications associated with the novel coronavirus.

Source: www.mobihealthnews.com